All cases hospitalized with COVID-19 who had severe illness requiring life support were not vaccinated
According to a US Centers for Disease Control and Prevention study, the Pfizer/BioNTech COVID-19 vaccine is 93% effective against COVID-19 hospitalization in young people.
In hospitalized patients aged 12 to 18 years in the US, the effectiveness of two doses of the Pfizer/BioNTech vaccine against COVID-19 hospitalizations from June to September this year was 93%, the CDC said.
Study findingsThis, the agency said, could help reinforce the importance of vaccination to protect American youth from the virus.
FDA may approve mix and match of COVID-19 booster shots
To reach these conclusions, CDC looked at this effectiveness in a trial-negative, case-control study at 19 pediatric hospitals in 16 states, which included 179 hospitalized patients and 285 controls.
43 percent of case-patients were admitted to the intensive care unit, 16% received life support during hospitalization and 2% of critically ill patients died.
The agency noted that all 29 critically ill patients and both deaths occurred in unvaccinated patients.
Seventy-two percent of those analyzed had at least one underlying condition, including obesity, and 68% attended school individually.
Case patients were hospitalized with symptomatic COVID-19-like illness and a positive SARS-CoV-2 reverse transcription-polymerase chain reaction or antigen test result.
Information on baseline demographic characteristics, clinical information about current disease, and SARS-CoV-2 testing history was obtained through parent or guardian interviews as well as review of electronic medical records .
Patients were considered to have received COVID-19 vaccination based on source documentation or plausible self-report, although neither Moderna Vaccines nor Johnson & Johnson Vaccines were authorized for people under 18 years of age at the time of evaluation.
Individuals classified exclusively as non-vaccinated or fully vaccinated were included in the study and patients with partial immunization were excluded from the analysis.
FDA panel endorses Johnson & Johnson COVID-19 vaccine booster with a gap of 2 months for 18 more UPs
The researchers used “descriptive statistics” to compare the characteristics of case patients and controls, including the Pearson chi-square test or Wilcoxon rank-sum test, and vaccine effectiveness against COVID-19 hospitalization, which is calculated The odds of absolute COVID-19 were compared by comparison. Vaccination between case patients and controls determined from a logistic regression model.
Models were adjusted for US census area, calendar month of hospital admission, age, sex, and race/ethnicity. While underlying health conditions and social vulnerability index were also assessed, they were not included in the final model because they did not change the vaccination odds ratio by more than 5%.
Sensitivity analyzes were performed and vaccine effectiveness was also stratified by age groups in addition to statistical analyzes reviewed by the agency and other participating institutions.
Case patients more often lived in areas of high social vulnerability, and vaccination coverage was 3% among case patients and 33% among controls.
Diabetes was more prevalent among patients, whereas neurological or neurological disorders were more prevalent among controls.
While the findings were reportedly consistent with efficacy data from the Pfizer/BioNTech clinical trial among individuals aged 12-15 years, the CDC wrote that that trial was not powered to assess efficacy against hospitalized COVID-19. it was done.
The CDC reported that, as of Monday, 46% of American children and adolescents aged 12-15 and 54% of those 16-17 years old had been fully vaccinated against COVID-19.
“These data suggest that increasing vaccination coverage among this group may reduce the incidence of severe COVID-19 in the United States. In addition, as school attendance increases, severe COVID-19 among adolescents increases.” Multi-component preventive measures, including vaccination, are imperative to reduce the incidence of stroke,” the researchers concluded.
the White House announced Wednesday That children ages 5 to 11 will be able to receive the Pfizer/BioNTech COVID-19 shot in a matter of weeks.